TABLE 1

Molecular weight (MW), mean rat plasma (f_u,p) and brain homogenate (f_u,b) unbound fractions, and single-dose-derived neuromatrix AUC values for the nine commercial and two proprietary compounds evaluated in rats

Compound	MW	f_u,p^{^a}	f_u,b^{^a}	Plasma		CSF		Brain
Compound	MW	f_u,p^{^a}	f_u,b^{^a}	AUC_0-Tlast	AUC_0-∞	AUC_0-Tlast	AUC_0-∞	AUC_0-Tlast	AUC_0-∞
				ng · h/ml		ng · h/ml		ng · h/ml
Carbamazepine^{^b}	236	0.222	0.0900	2270	2280	456	458	2540	2550
Citalopram^{^b}	324	0.355	0.0285	930	958	401	421	12,500	12,900
Ganciclovir^{^b}	255	0.972	0.855	1700	1720	78.4	82.5	170	182
Metoclopramide^{^b}	300	0.635	0.329	365	367	418	420	629	635
Norclozapine^{^c}	313	0.0625	0.00569	346	570	4.80	8.91	221	699
Quinidine^{^b}	324	0.265	0.0364	4920	5310	302	304	1850	1880
Risperidone^{^c}	411	0.0798	0.0699	409	441	11.3	11.9	108	130
9-Hydroxyrisperidone^{^c}	427	0.129	0.0755	184	342	3.28	12.2	13.5	69.0
Thiopental^{^b}	242	0.111	0.0986	216	244	16.4	16.6	209	215
PF-4778574^{^c}	391	0.0476	0.0195	122	131	3.46	5.40	131	150
CE-157119^{^c}	310	0.0145	0.00506	302	479	6.42	8.12	3360	5570

↵a For commercial compounds, mean values were reported by Liu et al. (2009a).
↵b T_last is 7 h postdose.
↵c T_last is 2 h postdose.